BioSpace News Archive

Vedanta Biosciences today announced that members of its executive team will participate at the following investor conferences.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival (DFS) for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced urothelial carcinoma versus observation.

Theralase Technologies Inc. is focused on the safe and effective destruction of various cancers, bacteria and viruses, when light or radiation activated.

Panavance Therapeutics Inc. today announced it will present at the BIO Investor Forum on Tuesday, October 17 at 10 a.m. PT.

Organogenesis Holdings Inc. today announced that third quarter of fiscal year 2023 financial results will be reported after the market closes on Thursday, November 9th.

Venus Concept Inc. today announced that it has finalized an agreement with its lenders, City National Bank of Florida (“CNB”) and Madryn Asset Management, LP and affiliates (“Madryn”), to restructure its existing debt obligations, improving the Company’s overall financial position by deferring certain principal and interest payments under its senior debt and exchanging a portion of its convertible notes for preferred stock.

SAB Biotherapeutics today announced that the SAB Board of Directors has approved the appointment of Andrew Moin to the Company’s Board of Directors.

Vivos Therapeutics, Inc. today announced it has entered into an exclusive distribution agreement with NOUM DMCC (“Noum”), a Dubai-based company focused on diagnostic testing and treatment product distribution for healthcare providers and hospital networks treating obstructive sleep apnea patients throughout the Middle East-North Africa (MENA) region.

Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that all patients in the ongoing phase 2a study in advanced hepatocellular carcinoma (HCC) has now dosed at least two treatment cycles and the treatment continues to show very promising clinical benefit.

Agenus Inc. today announced that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESMO) Conference on Sunday, October 22, 2023.